COMMUNIQUÉS West-GlobeNewswire

GENFIT: FDA and EMA Grant GENFIT’s Elafibranor Orphan Drug Designation for Primary Biliary Cholangitis (PBC)
29/07/2019
FDA and EMA Grant GENFIT’s Elafibranor Orphan Drug Designation for Primary Biliary Cholangitis (PBC) Lille (France), Cambridge (Massachusetts, United States), July 29, 2019 – GENFIT (Nasdaq and Euronext: GNFT) , a late- [...]
GENFIT : La FDA et l’EMA accordent la désignation d’Orphan Drug à elafibranor pour le traitement de la Cholangite Biliaire Primitive (PBC)
29/07/2019
La FDA et l’EMA accordent la désignation d’Orphan Drug à elafibranor pour le traitement de la Cholangite Biliaire Primitive (PBC) Lille (France), Cambridge (Massachusetts, États-Unis), le 29 juillet 2019 – GENFIT ( [...]
Sanofi delivered solid growth in Q2 2019
29/07/2019
Paris, July 29, 2019 Sanofi delivered solid growth in Q2 2019 Q2 2019 Change Change at CER H1 2019 Change Change at CER IFRS net sales reported €8,628m +5.5% +3.9% €17,019m +5.9% +4.1% IFRS net income reported -€87m - [...]
Sanofi affiche une croissance solide au deuxième trimestre 2019
29/07/2019
Paris, le 29 juillet 2019 Sanofi affiche une croissance solide au deuxième trimestre 2019 T2 2019 Variation Variation à TCC S1 2019 Variation Variation à TCC Chiffre d’affaires net IFRS publié €8 628m +5,5% +3,9% €17 [...]
Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
29/07/2019
PARAGON study narrowly misses statistical significance on the primary endpoint; overall safety profile confirmed Totality of evidence suggests potential clinically important benefit; results will be presented in [...]
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26/07/2019
WALTHAM, Mass. and CRESTWOOD, Ky., July 26, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program
26/07/2019
Sanofi Provides Disputed Termination Notice THE WOODLANDS, Texas,, July 26, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), received preliminary topline results from Sanofi for three Phase 3 [...]
Diversicare to Announce Second Quarter 2019 Financial Results on Thursday, August 1, 2019
26/07/2019
BRENTWOOD, Tenn., July 26, 2019 (GLOBE NEWSWIRE) -- Diversicare Healthcare Services, Inc. (NASDAQ:DVCR) today announced that it is scheduled to report financial results for its second quarter ended June 30, 2019, on [...]
Sanofi : Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon
26/07/2019
Sanofi provides update on Zynquista TM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon PARIS – July 26, 2019 – Sanofi today announced topline results from three Phase 3 trials of Zynquista [...]
Sanofi : Sanofi fournit des informations actualisées sur ZynquistaTM (sotagliflozine) dans le traitement du diabète de type 2 et sa collaboration avec Lexicon
26/07/2019
Sanofi fournit des informations actualisées sur Zynquista TM (sotagliflozine) dans le traitement du diabète de type 2 et sa collaboration avec Lexicon Paris – Le 26 juillet 2019 – Sanofi annonce aujourd’hui les premiers [...]
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
26/07/2019
BOTHELL, Wash., July 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]
priMED Medical Products Appoints Lucas Ethier as Executive Vice President
26/07/2019
Company fortifies its commitment to market growth, product focus and worldwide expansion EDMONTON, Alberta, Canada, July 26, 2019 (GLOBE NEWSWIRE) -- priMED Medical Products Inc. (priMED), a global medical product [...]
Sanofi : Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer
26/07/2019
Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer PARIS – July 26, 2019 – Following Olivier Brandicourt’s decision to claim his pension rights as of September 1, 2019, the Board of [...]
Sanofi : Information sur les conditions de départ d’Olivier Brandicourt, Directeur Général
26/07/2019
Information sur les conditions de départ d’Olivier Brandicourt, Directeur Général PARIS – 26 juillet 2019 – Faisant suite à la décision d’Olivier Brandicourt de faire valoir ses droits à la retraite à compter du 1 er [...]
CROSSJECT : Résultats des votes de l'Assemblée Générale Mixte du 20 juin 2019
26/07/2019
Communiqué de Presse Crossject : Résultats des votes de l’Assemblée Générale Mixte du 20 juin 2019 Dijon, le 26 Juillet 2019 L’assemblée générale mixte des actionnaires de CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ [...]
Abeona Therapeutics annonce des données intermédiaires positives provenant de l'essai clinique de phase 1/2 sur la thérapie génique ABO-102 dans la MPS III A
26/07/2019
Développement neurocognitif des patients les plus jeunes conservé 12 à 18 mois après le traitement ; les scores de développement restent dans la fourchette des enfants non affectés Amélioration solide et durable des [...]
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
26/07/2019
Orphazyme A/S Company announcement No. 19/2019 Company Registration No. 32266355 Copenhagen, July 26, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients [...]
Avinger to Announce Second Quarter 2019 Financial Results on July 31, 2019
26/07/2019
REDWOOD CITY, Calif., July 26, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for [...]
Generex Biotechnology Provides a Summary of Its Investor Conference Call Held on July 25, 2019
26/07/2019
Filing up-list application to Nasdaq Details on 1:1 Shareholder stock dividend Spin-out of NuGenerex Immuno-Oncology as a separately-traded public company Merger of NGIO with Kiromic Payoff of notes Recording available [...]

Pages